MDX-060 Medarex

Current Opinion in Investigational Drugs

Volumn 6, Issue 12, 2005, Pages 1266-1271

  Hu, Xiu Feng ^a   Xing, Pei Xiang ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AURISTATIN E; BORTEZOMIB; CD30 ANTIGEN; CD30 MONOCLONAL ANTIBODY; IMMUNOTOXIN; LYMPHOCYTE ANTIBODY; MDX 060; MONOCLONAL ANTIBODY; SGN 30; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG TARGETING; ENZYME DEFECT; HODGKIN DISEASE; HUMAN; INFUSION REACTION; LARGE CELL LYMPHOMA; LYMPHOMA; NONHUMAN; PNEUMONIA; PROTEIN FUNCTION; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE-CELL;

EID: 29444434681     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. 453000 Medarex files IND for MDX-060. Medarex Inc PRESS RELEASE 2002 May 29
2. 457812 The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, Chace DF, Siegall CB, Francisco JA CANCER RES 2002 62 13 3736-3742
3. 472939 The new fully human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against Hodgkin lymphoma. Borchmann P, Treml JF, Graziano RF, Schnell R, Engert A, Davi TA BLOOD 2002 100 11 Abs 2258
4. 473263 American Society of Hematology - 44th Annual Meeting and Exposition (Part III) - Overnight Report, Philadelphia, PA, USA. Adekale M IDDB MEETING REPORT 2002 December 06-10
5. 473348 Medarex announces fully human antibody MDX-060 demonstrates antitumor activity in animal models. Medarex Inc PRESS RELEASE 2002 December 09
6. 476240 Medarex Inc - presentation at the JP Morgan HQ 21st Annual Healthcare Conference. Medarex Inc COMPANY PRESENTATION 2003 January 06-09
7. 516666 Medarex announces complete and partial responses observed in phase I/II clinical study of MDX-060 at ASH meeting. Medarex Inc PRESS RELEASE 2003 December 09
8. 516997 Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's disease (HD) and anaplastic large cell lymphoma (ALCL). Ansell S, Byrd J, Horwitz S, Davis T, Borchmann P, Engert A, Strair R, Khan K, Keler T, Graziano R, Blanset D et al BLOOD 2003 102 11 Abs 632
9. 535135 Medarex announces 2003 fourth quarter and year-end financial results. Medarex Inc PRESS RELEASE 2004 February 26
10. 543643 Medarex's MDX-060 shows promise in Hodgkin's disease trial; MDX-010 gets orphan status. Medarex Inc PRESS RELEASE 2004 June 09
11. 553944 Anti-Cancer Drug Discovery and Development - Strategic Research Institute's Sixth Annual Summit, Philadelphia, PA, USA. Zhu Z, Williams B IDDB MEETING REPORT 2004 July 21-23
12. 558377 Medarex. Samad TT BEAR STEARNS CO INC 2004 August 23
13. 558587 The human anti-CD30 antibody 5F11 showns in vivo activity against malignant lymphoma. Borchmann P, Treml J, Hansen H, Gottstein C, Schnell R, Steak O, Zhang H, Davis T, Keler T, Diehl V BLOOD 2003 102 10 3737-3742
14. 559900 Monoclonal Antibodies in Cancer - Fourth International Congress (Part I), Colorado Springs, CO, USA. Horak ID IDDB MEETING REPORT 2004 September 03-06
15. 562787 Medarex's Hodgkin's disease antibody receives US orphan status. Medarex Inc PRESS RELEASE 2004 October 06
16. 573865 Phase II study of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodgkin's disease. Leonard JP, Rosenblatt JD, Bartlett NL, Gopal A, Younes A, Fisher D, Foss F, Forero A, Bernstein S, Cheson B, Carabasi MH et al BLOOD 2004 104 11 Abs 2635
17. 573866 Phase I/II, open-label, dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30+ lymphoma. Ansell SM, Byrd JC, Horwitz SM, Borchmann P, Engert A, Strair R, Khan KD, Fischkoff SA, Yellin M BLOOD 2004 104 11 Abs 2636
18. 574144 The human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib induced apoptosis. Pogge E, Boell B, Tawadros S, Reiners K, Borchmann P, Hansen H, Graziano R, Yellin M, Engert A BLOOD 2004 104 11 Abs 3295
19. 574562 Medarex announces complete and partial responses observed in clinical study of MDX-060 at ASH meeting. Medarex Inc PRESS RELEASE 2004 December 06
20. 619824 Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. Heuck F, Ellermann J, Borchmann P, Rothe A, Hansen H, Engert A, von Strandmann EP J IMMUNOTHER 1997 2004 27 5 347-353
21. 619825 Immunotherapy of Hodgkin's lymphoma. Borchmann P, Schnell R, Engert A EUR J HAEMATOL SUPPL 2005 75 66 159-165
22. 627466 Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V NATURE 1982 299 5878 65-67
23. 627467 CD30 in normal and neoplastic cells. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G CLIN IMMUNOL 1999 90 2 157-164
24. 627468 CD30: Expression and function in health and disease. Horie R, Watanabe T SEMIN IMMUNOL 1998 10 6 457-470
25. 627469 CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G J IMMUNOL 1999 163 1 194-205
26. 627470 Reverse signaling via CD30 ligand. Wiley SR, Goodwin FIG, Smith CA J IMMUNOL 1996 157 8 3635-3639
27. 627472 TNF/TNFR family members in costimulation of T cell responses. Watts TH ANNU REV IMMUNOL 2005 23 23-68
28. 627473 Induction of nuclear factor κB by the CD30 receptor is mediated by TRAF1 and TRAF2. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB MOL CELL BIOL 1997 17 3 1535-1542
29. 627475 TCR-Independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. Harlin H, Podack E, Boothby M, Alegre ML J IMMUNOL 2002 169 5 2451-2459
30. 627476 Hodgkin's lymphoma and CD30 signal transduction. Hone R, Higashihara M, Watanabe T INT J HEMATOL 2003 77 1 37-47
31. CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299. Hubinger G, Muller E, Scheffrahn I, Schneider C, Hildt E, Singer BB, Sigg I, Graf J, Bergmann L ONCOGENE 2001 20 5 590-598
32. 627478 CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells. Hubinger G, Schneider C, Stohr D, Ruff H, Kirchner D, Schwanen C, Schmid M, Bergmann L, Muller E EXP HEMATOL 2004 32 4 382-389
33. 627479 Pleiotropic signal transduction mediated by human CD30: A member of the tumor necrosis factor receptor (TNFR) family. Schneider C, Hubinger G LEUK L YMPHOMA 2002 43 7 1355-1366
34. 627480 Signal transduction in anaplastic large cell lymphoma cells (ALCL) mediated by the tumor necrosis factor receptor CD30. Schneider C, Stohr D, Merz H, Hubinger G LEUK LYMPHOMA 2004 45 5 1009-1015
35. 627485 CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Gloghini A, Wehnes E, Wright B, Boiani N, Aldinucci D, Gattei V, Zagonel V, Smith CA, Kadin ME, von Schilling C, Goodwin FIG et alAM J PATHOL 1996 149 2 469-481
36. 627487 Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG BLOOD 1994 83 8 2045-2056
37. 627489 CD30 ligand in lymphoma patients with CD30+ tumors. Younes A, Consoli U, Snell V, Clodi K, Kliche KO, Palmer JL, Gruss HJ, Armitage R, Thomas EK, Cabanillas F, Andreeff M J CLIN ONCOL 1997 15 11 3355-3362
38. 627490 Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. Zinzani PL, Pileri S, Bendandi M, Buzzi M, Sabattini E, Ascani S, Gherlinzoni F, Magagnoli M, Albertini P, Tura S J CLIN ONCOL 1998 16 4 1532-1537
39. 627491 The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A BLOOD 2003 102 10 3737-3742
40. 627492 CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: Apoptosis or cell-cycle arrest? Levi E, Pfeifer WM, Kadin ME BLOOD 2001 98 5 1630-1632
41. 627493 Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Mir SS, Richter BW, Duckett CS BLOOD 2000 96 13 4307-4312
42. 627495 Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, Saito I, Higashihara M, Mori S, Kadin ME, Watanabe T ONCOGENE 2002 21 16 2493-2503
43. 627497 The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis. Boll B, Hansen H, Hauck F, Reiners K, Borchmann P, Rothe A, Engert A, Pogge von Strandmann E BLOOD 2005 106 5 1839-1842
44. 637142 Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated Pseudomonas exotoxin. Rozemuller H, Chowdhury PS, Pastan I, Kreitman RJ INT J CANCER 2001 92 6 861-870
45. 637144 In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF CON CANCER RES 2005 11 2 Pt 1843-852